SLC5A2 and hydrops fetalis: The administration of SGLT2 inhibitors can significantly reduce the risk of MACEs (RR 0.79; 95% CI: 0.71–0.88; p for heterogeneity 0.74; I2 = 0%; p < 0.01) (Figure 5), CV death (RR 0.85; 95% CI: 0.73–0.98; p for heterogeneity 0.64; I2 = 0%; p = 0.02) (Figure 5), HF (RR 0.66; 95% CI: 0.58–0.75; p for heterogeneity 0.80; I2 = 0%; p < 0.01) (Figure 5), but not reduce the risk of all-cause death (random: RR 0.84; 95% CI: 0.69–1.04; p for heterogeneity 0.05; I2 = 67%; p = 0.11) (Figure 5).